Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Liquid product physical issue, Poor quality product administered, Product colour issue, Somnolence
Clinical narrative: Felt horrible after the booster dose; Slept for hours after the booster dose; Recieved booster dose was grey in colour and contained particles which was different from primary series; Booster dose had particles in it that are different from the Primary series; Booster dose was grey in colour; This spontaneous case was reported by a patient and describes the occurrence of FEELING ABNORMAL (Felt horrible after the booster dose), SOMNOLENCE (Slept for hours after the booster dose), POOR QUALITY PRODUCT ADMINISTERED (Recieved booster dose was grey in colour and contained particles which was different from primary series), LIQUID PRODUCT PHYSICAL ISSUE (Booster dose had particles in it that are different from the Primary series) and PRODUCT COLOUR ISSUE (Booster dose was grey in colour) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Epilepsy (had a long history). Concurrent medical conditions included Brain damage (had a long history, started when he was a child well before he took the Moderna Covid-19 vaccine) and Short-term memory loss (had a long history, started when he was a child well before he took the Moderna Covid-19 vaccine). Concomitant products included CARIPRAZINE HYDROCHLORIDE (VRAYLAR) for an unknown indication.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In February 2022, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Recieved booster dose was grey in colour and contained particles which was different from primary series), LIQUID PRODUCT PHYSICAL ISSUE (Booster dose had particles in it that are different from the Primary series) and PRODUCT COLOUR ISSUE (Booster dose was grey in colour). On an unknown date, the patient experienced FEELING ABNORMAL (Felt horrible after the booster dose) and SOMNOLENCE (Slept for hours after the booster dose). At the time of the report, FEELING ABNORMAL (Felt horrible after the booster dose), SOMNOLENCE (Slept for hours after the booster dose), POOR QUALITY PRODUCT ADMINISTERED (Recieved booster dose was grey in colour and contained particles which was different from primary series), LIQUID PRODUCT PHYSICAL ISSUE (Booster dose had particles in it that are different from the Primary series) and PRODUCT COLOUR ISSUE (Booster dose was grey in colour) outcome was unknown.            Patient had no reaction to first and second dose. Patient might not be taking Vraylar anymore. Patient lost focus during conversation. No treatment medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2022: Follow-up was received and included no significant information.